HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics

More filters

Study design
Intervention type
Study phase
232studies shown
Showing 1-12 of 232
Drug study icon
RecruitingNCT04478838

"Extended" (Alternate Day) Antipsychotic Dosing

Official study title

"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"

Recruiting in Canada
SchizophreniaMedication studyAges 18+
Countries
Canada
Sponsor
Centre for Addiction and Mental Health (Hospital / academic medical center)
Drug study icon
RecruitingNCT07420283

Adding brenipatide or placebo to buprenorphine with or without naloxone for opioid use

About this title

A Study of Brenipatide in Participants With Opioid Use Disorder

Read the official source — NCT07420283
Official study title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)

Recruiting in Canada
AddictionMedication studyAges 18–75
Countries
Canada, United States, United Kingdom
Sponsor
Eli Lilly and Company
Drug study icon
RecruitingNCT06887192

ML-007C-MA for psychosis associated with Alzheimer’s disease

About this titleRead the official source — NCT06887192
Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Recruiting in Canada
SchizophreniaMedication studyAges 55–90
Countries
Canada, United States, France, + 12 others
Sponsor
MapLight Therapeutics
Drug study icon
RecruitingNCT07196501

Osavampator or placebo to maintain depression treatment response

About this titleRead the official source — NCT07196501
Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Recruiting in Canada
DepressionMedication studyAges 18+
Countries
Canada, United States, Australia, + 8 others
Sponsor
Neurocrine Biosciences (Biotech company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.